Back to Dashboard

AC220-168

AML-MDS•NCT06578247•Last updated: 2/17/2026

Recruiting

Study Design

Study Drug

Quizartinib/ Placebo

Mechanism of Action

class III receptor tyrosine kinases

Sponsor

Unknown

Design

III

Control Arm

-

Criteria

Inclusion Criteria

Untreated & FLT3-ITD(-)

Age: ≥18 years Phase: III

Exclusion Criteria

Enrollment

Progress1 / 4

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620